BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99:2195-203. [PMID: 15555002 DOI: 10.1111/j.1572-0241.2004.30509.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology 2022;163:137-51. [PMID: 35738725 DOI: 10.1053/j.gastro.2022.04.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Barberio B, Savarino EV, Black CJ, Ford AC. Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00905-8. [PMID: 34425274 DOI: 10.1016/j.cgh.2021.08.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Zheng L, Lu W, Xiao Q, Lai Y, Fan H, Sun Y, Huang D, Wang Y, Li Z, Jiang Z, Liu X, Zhang L, Zuo D, Shou Z, Tang Q, Huang H, Yang Y, Tang Z, Xiao J. Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial. Sci Rep 2021;11:13894. [PMID: 34230526 DOI: 10.1038/s41598-021-92990-7] [Reference Citation Analysis]
4 Rokkas T, Ekmektzoglou K, Niv Y. Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies. Ann Gastroenterol 2021;34:535-46. [PMID: 34276193 DOI: 10.20524/aog.2021.0619] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Bosman M, Elsenbruch S, Corsetti M, Tack J, Simrén M, Winkens B, Boumans T, Masclee A, Keszthelyi D. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:459-73. [PMID: 33765447 DOI: 10.1016/S2468-1253(21)00023-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
6 Colomier E, Algera J, Melchior C. Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea. Front Pharmacol 2020;11:629026. [PMID: 33679391 DOI: 10.3389/fphar.2020.629026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fukudo S, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T, Sato K, Shiotani A, Naito Y, Fujikawa Y, Hokari R, Masaoka T, Fujimoto K, Kaneko H, Torii A, Matsueda K, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol 2021;56:193-217. [PMID: 33538894 DOI: 10.1007/s00535-020-01746-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
8 Enck P, Klosterhalfen S. Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders. Front Psychiatry 2020;11:797. [PMID: 33192627 DOI: 10.3389/fpsyt.2020.00797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
9 Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, Houghton LA, Ford AC. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut 2020;69:74-82. [PMID: 30996042 DOI: 10.1136/gutjnl-2018-318160] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 35.5] [Reference Citation Analysis]
10 Lackner JM, Jaccard J, Radziwon CD, Firth RS, Gudleski GD, Hamilton F, Katz LA, Keefer L, Krasner SS, Ma CX, Sitrin MD, Brenner DM. Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up. Am J Gastroenterol 2019;114:330-8. [PMID: 30429592 DOI: 10.1038/s41395-018-0396-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
11 Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM; ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113:1-18. [PMID: 29950604 DOI: 10.1038/s41395-018-0084-x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 151] [Article Influence: 46.7] [Reference Citation Analysis]
12 Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol 2018;13:259-88. [PMID: 30581501 DOI: 10.5114/pg.2018.78343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
13 Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Current Medical Research and Opinion 2019;35:461-72. [DOI: 10.1080/03007995.2018.1533456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
14 Oh SJ, Tashjian VC, Mirocha J, Nagar M, Mathur R, Lin E, Chua KS, Rezaie A, Pimentel M, Pichetshote N. Declining Rates of Referral for Irritable Bowel Syndrome Without Constipation at a Tertiary Care Center. Dig Dis Sci 2019;64:182-8. [PMID: 30324554 DOI: 10.1007/s10620-018-5302-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Chang C. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. Clin Exp Gastroenterol 2018;11:335-45. [PMID: 30288076 DOI: 10.2147/CEG.S167031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
16 Lenhart A, Ferch C, Shaw M, Chey WD. Use of Dietary Management in Irritable Bowel Syndrome: Results of a Survey of Over 1500 United States Gastroenterologists. J Neurogastroenterol Motil 2018;24:437-51. [PMID: 29886578 DOI: 10.5056/jnm17116] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
17 Zhu L, Ma Y, Ye S, Shu Z. Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis. Evid Based Complement Alternat Med. 2018;2018:2890465. [PMID: 29977312 DOI: 10.1155/2018/2890465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
18 Lacy BE, Nicandro JP, Chuang E, Earnest DL. Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. Therap Adv Gastroenterol. 2018;11:1756284818771674. [PMID: 29774051 DOI: 10.1177/1756284818771674] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
19 Gupta K, Ghuman HS, Handa SV. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. Clin Med Insights Gastroenterol 2017;10:1179552217728905. [PMID: 28894393 DOI: 10.1177/1179552217728905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L, Lin L. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0172846. [PMID: 28291778 DOI: 10.1371/journal.pone.0172846] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
21 Enck P, Klosterhalfen S, Weimer K. Unsolved, Forgotten, and Ignored Features of the Placebo Response in Medicine. Clinical Therapeutics 2017;39:458-68. [DOI: 10.1016/j.clinthera.2016.11.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
22 Li ZY, Zhang N, Wen S, Zhang J, Sun XL, Fan XM, Sun YH. Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome. Clin Res Hepatol Gastroenterol. 2017; Epub ahead of print. [PMID: 28215540 DOI: 10.1016/j.clinre.2016.12.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
23 Clavé P, Tack J. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. Therap Adv Gastroenterol 2017;10:311-22. [PMID: 28246548 DOI: 10.1177/1756283X16681708] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
24 Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016;111:1824-1832. [PMID: 27725652 DOI: 10.1038/ajg.2016.434] [Cited by in Crossref: 173] [Cited by in F6Publishing: 173] [Article Influence: 28.8] [Reference Citation Analysis]
25 Lacy BE. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil. 2016;28:26-35. [PMID: 26690872 DOI: 10.1111/nmo.12716] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
26 Saps M, van Tilburg MAL, Lavigne JV, Miranda A, Benninga MA, Taminiau JA, Di Lorenzo C. Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials. Neurogastroenterol Motil 2016;28:1619-31. [DOI: 10.1111/nmo.12896] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
27 Bielefeldt K. Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System. Dig Dis Sci 2016;61:2655-65. [DOI: 10.1007/s10620-016-4162-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
28 Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, Nakashima Y, Haruma K. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol. 2016;51:874-882. [PMID: 26800997 DOI: 10.1007/s00535-016-1165-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
29 Nee J, Zakari M, Lembo AJ. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. Expert Opin Pharmacother 2015;16:2781-92. [PMID: 26558923 DOI: 10.1517/14656566.2015.1101449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
30 Elsenbruch S, Enck P. Placebo effects and their determinants in gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2015;12:472-85. [DOI: 10.1038/nrgastro.2015.117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 86] [Article Influence: 14.7] [Reference Citation Analysis]
31 Good L, Rosario R, Panas R. New therapeutic option for irritable bowel syndrome: Serum-derived bovine immunoglobulin. World J Gastroenterol 2015; 21(11): 3361-3366 [PMID: 25805945 DOI: 10.3748/wjg.v21.i11.3361] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
32 Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, Kanazawa M, Kamiya T, Sato K, Chiba T, Furuta K, Yamato S, Arakawa T, Fujiyama Y, Azuma T, Fujimoto K, Mine T, Miura S, Kinoshita Y, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11-30. [PMID: 25500976 DOI: 10.1007/s00535-014-1017-0] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
33 Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Quigley EM; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 Suppl 1:S2-26; quiz S27. [PMID: 25091148 DOI: 10.1038/ajg.2014.187] [Cited by in Crossref: 350] [Cited by in F6Publishing: 328] [Article Influence: 43.8] [Reference Citation Analysis]
34 Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1149-72.e2. [PMID: 25224525 DOI: 10.1053/j.gastro.2014.09.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 9.9] [Reference Citation Analysis]
35 O'Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32-48. [PMID: 25078296 DOI: 10.1016/j.bbr.2014.07.027] [Cited by in Crossref: 747] [Cited by in F6Publishing: 809] [Article Influence: 93.4] [Reference Citation Analysis]
36 Shah E, Pimentel M. Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome. Aliment Pharmacol Ther 2014;39:973-83. [DOI: 10.1111/apt.12692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
37 Au Yeung ST, Colagiuri B, Lovibond PF, Colloca L. Partial reinforcement, extinction, and placebo analgesia. Pain 2014;155:1110-7. [PMID: 24602997 DOI: 10.1016/j.pain.2014.02.022] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
38 Lewis JH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Review of Gastroenterology & Hepatology 2014;4:13-29. [DOI: 10.1586/egh.09.72] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
39 Lacy BE, Oʼshana T. Clinical Pearls for Irritable Bowel Syndrome: Management of the Diarrhea-Predominant Subtype. Gastroenterology Nursing 2014;37:392-405. [DOI: 10.1097/sga.0000000000000056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Shah E, Triantafyllou K, Hana AA, Pimentel M. Adverse events appear to unblind clinical trials in irritable bowel syndrome. Neurogastroenterol Motil 2014;26:482-8. [PMID: 24350975 DOI: 10.1111/nmo.12289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
41 Tong K, Nicandro JP, Shringarpure R, Chuang E, Chang L. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 2013;6:344-57. [PMID: 24003335 DOI: 10.1177/1756283X13491798] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
42 Anastasi JK, Capili B, Chang M. Managing irritable bowel syndrome. Am J Nurs 2013;113:42-52; quiz 54, 53. [PMID: 23764698 DOI: 10.1097/01.NAJ.0000431911.65473.35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
43 Harris LA, Chang L. Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome. Womens Health (Lond) 2007;3:15-27. [PMID: 19803861 DOI: 10.2217/17455057.3.1.15] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Dellon ES, Ringel Y. Treatment of functional diarrhea. Curr Treat Options Gastroenterol 2006;9:331-42. [PMID: 16836952 DOI: 10.1007/s11938-006-0015-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
45 Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012;36:437-448. [PMID: 22779693 DOI: 10.1111/j.1365-2036.2012.05208.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
46 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100. [PMID: 22754282 DOI: 10.2147/CEG.S290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100. [PMID: 22754282 DOI: 10.2147/CEG.S29023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
48 Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:991-1000. [PMID: 22613905 DOI: 10.1038/ajg.2012.131] [Cited by in Crossref: 204] [Cited by in F6Publishing: 217] [Article Influence: 20.4] [Reference Citation Analysis]
49 Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome. The American Journal of Medicine 2012;125:381-93. [DOI: 10.1016/j.amjmed.2011.08.026] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
50 Evangelista S. Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract. 2012;2012:936960. [PMID: 22272195 DOI: 10.1155/2012/936960] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
51 Harris LA, Heitkemper MM. Practical Considerations for Recognizing and Managing Severe Irritable Bowel Syndrome. Gastroenterology Nursing 2012;35:12-21. [DOI: 10.1097/sga.0b013e31823ff0e8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
52 Camilleri M. Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome. Clin Pharmacol Ther 2011;91:44-59. [DOI: 10.1038/clpt.2011.261] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
53 Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011;5:253-66. [PMID: 21927652 DOI: 10.5009/gnl.2011.5.3.253] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
54 Kwon JG, Park KS, Park JH, Park JM, Park CH, Lee KJ, Park HJ, Rhee JC; Korean Society of Neurogastroenterology and Motility. [Guidelines for the treatment of irritable bowel syndrome]. Korean J Gastroenterol 2011;57:82-99. [PMID: 21350320 DOI: 10.4166/kjg.2011.57.2.82] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
55 Fayyaz M, Lackner JM. Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther Clin Risk Manag. 2008;4:41-48. [PMID: 18728719 DOI: 10.2147/tcrm.s140] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
56 Saad RJ. Peripherally acting therapies for the treatment of irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40:163-182. [PMID: 21333906 DOI: 10.1016/j.gtc.2010.12.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
57 Tsynman DN, Thor S, Kroser JA. Treatment of Irritable Bowel Syndrome in Women. Gastroenterology Clinics of North America 2011;40:265-90. [DOI: 10.1016/j.gtc.2011.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
58 Schmulson M, Chang L. Review article: the treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther. 2011;33:1071-1086. [PMID: 21488913 DOI: 10.1111/j.1365-2036.2011.04637.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
59 Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol. 2010;7:565-581. [PMID: 20890316 DOI: 10.1038/nrgastro.2010.137] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 7.1] [Reference Citation Analysis]
60 Porto R. L’effet placebo : importance de la prise en charge. Sexologies 2011;20:52-61. [DOI: 10.1016/j.sexol.2011.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Shinozaki M, Kanazawa M, Kano M, Endo Y, Nakaya N, Hongo M, Fukudo S. Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial. Appl Psychophysiol Biofeedback. 2010;35:189-198. [PMID: 19997775 DOI: 10.1007/s10484-009-9125-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
62 Lynd LD, Najafzadeh M, Colley L, Byrne MF, Willan AR, Sculpher MJ, Johnson FR, Hauber AB. Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome. Value in Health 2010;13:411-7. [DOI: 10.1111/j.1524-4733.2009.00595.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
63 Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32:144-158. [PMID: 20412064 DOI: 10.1111/j.1365-2036.2010.04328.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 133] [Article Influence: 12.3] [Reference Citation Analysis]
64 Trentacosti AM, He R, Burke LB, Griebel D, Kennedy DL. Evolution of Clinical Trials for Irritable Bowel Syndrome: Issues in End Points and Study Design. American Journal of Gastroenterology 2010;105:731-5. [DOI: 10.1038/ajg.2010.12] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
65 Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010;105:866-875. [PMID: 20197759 DOI: 10.1038/ajg.2010.25] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
66 Lacy BE. Irritable bowel syndrome and disease severity: are we undertreating our patients? Expert Rev Gastroenterol Hepatol 2010;4:1-3. [PMID: 20136583 DOI: 10.1586/egh.09.71] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Duracinsky M, Chassany O. [How can an effective drug to treat irritable bowel syndrome be successfully developed?]. Gastroenterol Clin Biol 2009;33 Suppl 1:S26-34. [PMID: 19303535 DOI: 10.1016/S0399-8320(09)71522-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
68 Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009; 15(29): 3591-3596 [PMID: 19653335 DOI: 10.3748/wjg.15.3591] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
69 Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-43; quiz 1844. [PMID: 19471254 DOI: 10.1038/ajg.2009.223] [Cited by in Crossref: 193] [Cited by in F6Publishing: 165] [Article Influence: 14.8] [Reference Citation Analysis]
70 Enck P, Zipfel S, Klosterhalfen S. Der Placeboeffekt in der Medizin. Bundesgesundheitsbl 2009;52:635-42. [DOI: 10.1007/s00103-009-0849-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Adeyemo MA, Chang L. New treatments for irritable bowel syndrome in women. Womens Health (Lond) 2008;4:605-22; quiz 623. [PMID: 19072463 DOI: 10.2217/17455057.4.6.605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
72 Enck P, Vinson B, Malfertheiner P, Zipfel S, Klosterhalfen S. The placebo response in functional dyspepsia--reanalysis of trial data. Neurogastroenterol Motil 2009;21:370-7. [PMID: 19210629 DOI: 10.1111/j.1365-2982.2008.01241.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
73 Brandt LJ, Chey WD, Foxx-orenstein AE, Quigley EM, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Moayyedi P. An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome: . American Journal of Gastroenterology 2009;104:S8-S35. [DOI: 10.14309/00000434-200901001-00002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
74 Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008;135:1877-91. [PMID: 18848833 DOI: 10.1053/j.gastro.2008.09.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
75 Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther. 2008;30:884-901. [PMID: 18555935 DOI: 10.1016/j.clinthera.2008.05.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
76 Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008;59:195-206. [PMID: 18667148 DOI: 10.1016/j.neuron.2008.06.030] [Cited by in Crossref: 374] [Cited by in F6Publishing: 320] [Article Influence: 26.7] [Reference Citation Analysis]
77 Klosterhalfen S, Enck P. Neurophysiology and psychobiology of the placebo response. Curr Opin Psychiatry 2008;21:189-95. [PMID: 18332669 DOI: 10.1097/YCO.0b013e3282f50c36] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
78 Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008;103:1217-25. [PMID: 18477346 DOI: 10.1111/j.1572-0241.2008.01808.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
79 Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008;6:545-555. [PMID: 18242143 DOI: 10.1016/j.cgh.2007.12.015] [Cited by in Crossref: 138] [Cited by in F6Publishing: 129] [Article Influence: 9.9] [Reference Citation Analysis]
80 Saad RJ, Chey WD. Recent developments in the therapy of irritable bowel syndrome. Expert Opinion on Investigational Drugs 2008;17:117-30. [DOI: 10.1517/13543784.17.2.117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
81 Videlock EJ, Chang L. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am. 2007;36:665-685, x. [PMID: 17950443 DOI: 10.1016/j.gtc.2007.07.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
82 Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther. 2007;25:1271-1281. [PMID: 17509095 DOI: 10.1111/j.1365-2036.2007.03313.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
83 Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98. [PMID: 17488783 DOI: 10.1136/gut.2007.119446] [Cited by in Crossref: 543] [Cited by in F6Publishing: 483] [Article Influence: 36.2] [Reference Citation Analysis]
84 Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102:1709-19. [PMID: 17509028 DOI: 10.1111/j.1572-0241.2007.01282.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 5.2] [Reference Citation Analysis]
85 Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007; 13(25): 3425-3429 [PMID: 17659688 DOI: 10.3748/wjg.v13.i25.3425] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
86 Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56:1770-1798. [PMID: 17488783 DOI: 10.1136/gut.2007.119446corr1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol. 2007;5:534-540. [PMID: 17428741 DOI: 10.1016/j.cgh.2007.03.004] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
88 Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006;24:183-205. [PMID: 16842448 DOI: 10.1111/j.1365-2036.2006.02938.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 7.0] [Reference Citation Analysis]
89 Heading R, Bardhan K, Hollerbach S, Lanas A, Fisher G. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006;24:207-236. [PMID: 16842449 DOI: 10.1111/j.1365-2036.2006.02937.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
90 Tort S, Balboa A, Marzo M, Carrillo R, Mínguez M, Valdepérez J, Alonso-Coello P, Mascort JJ, Ferrándiz J, Bonfill X, Piqué JM, Mearin F; Centro Cochrame Iberoamericano., Asociación Española de Gastroentología., Sociedad Española de Medicina de Familia y Comunitaria (SEMFYC). [Clinical practice guideline for irritable bowel syndrome]. Gastroenterol Hepatol 2006;29:467-521. [PMID: 17020681 DOI: 10.1157/13092567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
91 McLean PG, Borman RA, Lee K. 5-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci 2007;30:9-13. [PMID: 17126921 DOI: 10.1016/j.tins.2006.11.002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
92 Harris LA, Chang L. Irritable bowel syndrome: new and emerging therapies. Curr Opin Gastroenterol 2006;22:128-35. [PMID: 16462168 DOI: 10.1097/01.mog.0000208461.84513.f3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
93 Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491. [PMID: 16678561 DOI: 10.1053/j.gastro.2005.11.061] [Cited by in Crossref: 3154] [Cited by in F6Publishing: 2964] [Article Influence: 197.1] [Reference Citation Analysis]
94 Design of Treatment Trials Committee, Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538-1551. [PMID: 16678567 DOI: 10.1053/j.gastro.2005.11.058] [Cited by in Crossref: 221] [Cited by in F6Publishing: 218] [Article Influence: 13.8] [Reference Citation Analysis]
95 Ness TJ. Pelvic pain in women and men: recent findings. Curr Opin Anaesthesiol 2005;18:555-62. [PMID: 16534292 DOI: 10.1097/01.aco.0000182567.70798.a7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
96 Delvaux MM, Gay G. Drugs Affecting Visceral Sensitivity: Ready for the Prime Time? Dig Dis 2006;24:99-104. [DOI: 10.1159/000090313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
97 Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101:1069-79. [PMID: 16606352 DOI: 10.1111/j.1572-0241.2006.00459.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 101] [Article Influence: 7.2] [Reference Citation Analysis]
98 Whitehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006;101:1057-65. [PMID: 16573774 DOI: 10.1111/j.1572-0241.2006.00535.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
99 Gallo-Torres H, Brinker A, Avigan M. Alosetron: ischemic colitis and serious complications of constipation. Am J Gastroenterol 2006;101:1080-3. [PMID: 16696787 DOI: 10.1111/j.1572-0241.2006.00650.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
100 Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. BMJ. 2006;332:280-283. [PMID: 16455728 DOI: 10.1136/bmj.332.7536.280] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 3.3] [Reference Citation Analysis]
101 Enck P, Klosterhalfen S, Kruis W. Factors affecting therapeutic placebo response rates in patients with irritable bowel syndrome. Nat Rev Gastroenterol Hepatol 2005;2:354-5. [DOI: 10.1038/ncpgasthep0237] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
102 Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil. 2005;17:325-331. [PMID: 15916619 DOI: 10.1111/j.1365-2982.2005.00676.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 4.0] [Reference Citation Analysis]